* for medical professionals to read only
With the continuous update of clinical research evidence, the diagnostic standards and target values of hypertension have been adjusted
★ Expert comments
Professor Zhang Yuqing commented
"Physical reduction is the hard truth", which is often the catchphrase of all academic experts. Everything needs to be analyzed from two aspects. Blood pressure is a physiological indicator. On the one hand, the increase in blood pressure can cause harm to important organs from the perspective of hemodynamics . In addition, various reasons will lead to increased blood pressure, that is, hypertension is also a manifestation of clinical diseases.
Therefore, the treatment of hypertension requires the control of blood pressure to the target level (meet the standard); on the other hand, it requires active search for the causes and causes of increased blood pressure, and actively intervene in those reversible risk factors to treat comorbidities.
Antihypertensive treatment is not the whole of hypertension. Based on this, the 2022 China Hypertension Prevention and Treatment Guide is currently being actively revised. The guide will provide comprehensive guidance and suggestions for the prevention and treatment of hypertension in my country based on the theoretical basis of typing, grading and staged diagnosis and treatment of hypertension.
In recent years, a number of research on the antihypertensive targets of hypertension have been carried out at home and abroad. These research results have caused extensive discussions in the academic community, allowing us to more fully recognize the complexity of hypertension management and raise new questions for the in-depth research on hypertension in the future.
Based on current evidence, the overall target of antihypertensive treatment is more stringent. The target of antihypertensive treatment for hypertensive patients, including the elderly, should be reduced to below 140/90mmHg. If over-tolerant, it can be considered close to 130/80mmHg or below. Strengthen the monitoring of family blood pressure. If the blood pressure control level is low, even if the family blood pressure is controlled below 130/80mmHg and is well tolerated, the treatment of blood pressure should not be relaxed, otherwise it will lead to an increase in complications.
Professor Zhang Yuqing
MD, Chief Physician. Currently working in the Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences. He has been engaged in research and prevention and treatment of hypertension and cardiac target organ damage for a long time. He is good at the diagnosis and treatment of cardiovascular diseases such as difficult hypertension, heart failure, , etc.
focuses on research on evidence-based medicines such as large-scale clinical trials of hypertension, including the National Seventh Five-Year Plan "Clinical Trial of Systolic Hypertension in Elderly (SYST-CHINA), the National Ninth Five-Year Plan "The Treatment Research on Hypertension in the Treatment of Hypertension- Felodipine Reduction Complications" (FEVER), the National Eighteenth Five-Year Plan "Comprehensive Prevention and Treatment Research on Hypertension" (CHIEF), and the "Research on the Intervention of Normal High Value of Blood Pressure in China" (CHINOM), the National "13th Five-Year Plan" major chronic non-communicable disease prevention and control research on obesity and hypertension lifestyle and nutrition intervention technology and strategies, and the 2020 Capital Science and Technology Development Fund Remote Blood Pressure Management Project Leader.
is a co-coordinator of the European Society of Hypertension- China Hypertension Alliance Poststroke Optimization Treatment Research (ESH-CHL-SHOT), a member of the endpoint committee for acabose intervention prediabetes combined with coronary heart disease research (ACE).
is currently the executive director and secretary-general of the China Hypertension Alliance, deputy chairman of the Hypertension Branch of the China Healthcare International Exchange Promotion Association, chairman of the Youth Department, member of the Heart Failure Professional Committee of the Chinese Medical Association, and vice president of the Beijing Hypertension Prevention and Treatment Association.
European Society of Cardiology Fellow (FESC), International Society of Hypertension Fellow (ISHF), member of the European Society of Hypertension (ESH), member of the American College of Cardiology (ACCh), member of the Asia-Pacific Advisory Group of the International Society of Hypertension.
Journal of Clinical Hypertension, Deputy Editor of Journal of Hypertension, Hypertension Research, Blood Pressure, Chinese Journal of Cardiovascular Disease , Chinese Journal of Hypertension , Chinese Journal of Frontier Medicine and other journals.
participated in the writing of many domestic and foreign guidelines for the prevention and treatment of hypertension and related diseases and treatment suggestions. The important papers written have been cited by domestic and foreign guidelines for the prevention and treatment of hypertension and related diseases.He is a member of the Chinese Hypertension Prevention and Treatment Guidelines for 2005, 2010 and 2018, the author of the 2019 Chinese Medical Association's Grassroots Hypertension Diagnosis and Treatment Guidelines, a member of the 2020 Chinese Cardiovascular Disease First-level Prevention Guidelines for 2020, and the Deputy Chairman of the 2020 Grassroots Cardiovascular Disease Comprehensive Management Guidelines Committee.
0 Member of the Expert Group of the European Society of Hypertension "International Dynamic Blood Pressure Consensus" in 2013; Member of the Committee of the European Society of Hypertension "International Dynamic Blood Pressure Guide" in 2014, Member of the Committee of the 2017 Asian Family Blood Pressure and 2019 Asian Dynamic Blood Pressure Consensus, and Reviewer of the 2020 ISH International Hypertension Guide.
More practical knowledge of cardiovascular clinical?
Come and " Doctor Station APP" Take a look 👇
References:
[1]https://mp.weixin.qq.com/s?__biz=MzU4NzExMTE2MA==mid=2247617252idx=1sn=cc 695ca723d1d693e1add90f8386da36chksm=fdf24573ca85cc6518c357add496e80fee1c953067c61088c2cba3e2a0a24c159481aec39861token=331074801lang=zh_CN#rd
[2]Revision Committee of the "China Hypertension Prevention and Control Guidelines". Revised version of China's Hypertension Prevention and Treatment Guidelines in 2018 [J]. Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, 2019, 19(1): 1-44.
[3]Sun Yingxian, Zhao Lianyou, Tian Gang, et al. Consensus on Chinese Experts on Issues of Hypertension Emergencies [J]. Chinese Journal of Hypertension, 2022, 30(3): 207-218.
[4] Zhang Yuqing; Miao Huanhuan; Yang Shijie; Zhou Zhanyang;. Planning after action——Inspiration in important research on recent hypertension [J]. Chinese Journal of Interventional Cardiology, 2022, 07:518-521
Source of this article: Medical Cardiovascular Channel
Author of this article: shanluzuode
Review of this article: Professor Zhang Yuqing Fuwai Hospital of Chinese Academy of Medical Sciences
Illustrations of this article: Taishuai Gallery
Editor: Peng Jianping
Copyright statement
Original article Welcome to forward the circle of friends
- End -
Signature Manuscript
"Cardiovascular Channel of the Medical Industry" has long recruited online authors, 1. Clinical practical skills of cardiovascular internal medicine, misdiagnosed cases, clinical medication, and interesting content; 2. Interesting diagnosis and treatment stories of cardiovascular internal medicine; 3. Major progress in the cardiovascular internal medicine industry; 4. Others (Cardiovascular internal medicine is only interested in).
Welcome to share the article! We will provide you with a competitive royalty and a platform to showcase your talents. Submission email: [email protected] (reply to reply to the submission)
The medical community strives to ensure the accuracy and reliability of the published content when it is approved, but does not make any commitments and guarantees for the timeliness of the published content, as well as the accuracy and completeness of the cited materials (if any), and does not assume any responsibility arising from such content being outdated, the possible inaccuracy or incompleteness of the cited materials. Please check separately when using this or using it as the basis for decision-making.
